Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen

Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters

“…b Included (group B, helper antigen and ⁄ or adjuvant)): Bedrosian et al (2003), Butterfield et al (2003), Davis et al (2006), de Vries et al (2003), Escudier et al (2005), Grover et al (2006), Lau et al (2001), Linette et al (2005), Mackensen et al (2000), Nakai et al (2006, 2008), Ribas et al (2004), Schadendorf et al (2006), Trakatelli et al (2006),Tuettenberg et al (2006). Included (group A, helper antigen and ⁄ or adjuvant+):Akiyama et al (2005),Banchereau et al (2001Banchereau et al ( , 2005,Gilliet et al (2003),Hersey et al (2004Hersey et al ( , 2008,Jonuleit et al (2001),Lesimple et al (2006),Nestle et al (1998),Palucka et al (2003),Ribas et al (2009), Schuler-Thurner et al (2000,Slingluff et al (2003),Smithers et al (2003),Thurner et al (1999). c Included (group B, helper antigen and ⁄ or adjuvant)):Bercovici et al (2008),Nakai et al (2006), O'Rourke et al (2003), Viella et al (2004), von Euw et al (2008.…”

“…Included (DTH+): Akiyama et al (2005), Banchereau et al (2001), Chang et al (2002), Davis et al (2006), de Vries et al (2003), Dillman et al (2004), Escobar et al (2005), Hersey et al (2004, 2008), Jonuleit et al (2001), Kyte et al (2006), Lesimple et al (2006), Mackensen et al (2000), Nagayama et al (2003), Nakai et al (2006, 2008), Nestle et al (1998), O'Rourke et al (2003), Ridolfi et al (2006), Smithers et al (2003), Tuettenberg et al (2006), von Euw et al (2008). b Included (unchanged IFN-c secreting cells): Akiyama et al (2005), Banchereau et al (2001), Butterfield et al (2003), Chang et al (2002), Escobar et al (2005), Griffioen et al (2004), Jonuleit et al (2001), Krause et al (2002), Kyte et al (2006), Linette et al (2005), Nakai et al(2006, 2008),Palucka et al (2003),Ribas et al (2004), Ridolfi et al (2006,Salcedo et al (2006), Schuler-Thurner et al (2000,Smithers et al (2003),Thurner et al (1999),Tuettenberg et al (2006),Vilella et al (2004), von Euw et al (2008. Included (increased IFN-c secreting cells):Akiyama et al (2005),Banchereau et al (2001),Butterfield et al (2003),Chang et al (2002),Di Nicola et al (2004),Escobar et al (2005),Griffioen et al (2004),Jonuleit et al (2001),Krause et al (2002),Kyte et al (2006),Linette et al (2005),Nakai et al (2006Nakai et al ( , 2008,Palucka et al (2003),Ribas et al (2004Ribas et al ( , 2009),Ridolfi et al (2006),Salcedo et al (2006),Schuler-Thurner et al (2000,Smithers et al (2003),Thurner et al (1999),Tuettenberg et al (2006),Vilella et al (2004), von Euw et al (200...…”

Could hepatitis B vaccine act as an adjuvant to lower risk and relapses of cancer?

“…31 While none of the 10 non-HBsAg responding patients demonstrated objective clinical responses and disease stabilization, four of the nine HBsAg-responding patients did (P = 0.018). 31 Specific immune responses to melanoma and T cell responses to mitogens were increased in subjects responding to HBsAg. 31 Here, we want to briefly mention that HBV surface antigens may also exert similarities to melanocyte antigens as evidenced by associations of HBV-carrier frequency in vitiligo patients.…”

“…31 Specific immune responses to melanoma and T cell responses to mitogens were increased in subjects responding to HBsAg. 31 Here, we want to briefly mention that HBV surface antigens may also exert similarities to melanocyte antigens as evidenced by associations of HBV-carrier frequency in vitiligo patients. Vitiligo is a relatively frequent dermal disease characterized by the partial loss of melanocytes.…”

Trial watch

“…Since then, this approach has been tested in a consistent number of Phase I/II clinical trials that enrolled patients affected by a wide array of neoplasms including chronic myeloid leukemia (CML), 241 , 242 myeloma, 243 - 249 sarcoma, 218 , 250 glioma, 251 , 252 GBM, 253 - 255 breast carcinoma, 256 - 261 NSCLC, 262 - 265 melanoma, 179 , 184 , 191 , 193 , 266 - 282 HCC, 283 pancreatic carcinoma, 284 , 285 gastrointestinal malignancies, 286 , 287 biliary tract cancer, 284 CRC, 262 , 264 , 288 - 290 RCC, 291 - 293 ovarian carcinoma, 218 , 256 , 294 , 295 cervical carcinoma, 296 , 297 prostate cancer, 259 , 298 - 311 and other advanced malignancies 312 . Altogether, these clinical studies demonstrated that the use of DCs loaded ex vivo with purified TAAs is safe and results in the activation of TAA-specific immunity in a large proportion of patients, some of whom also exhibit partial or complete clinical responses.…”